Physician profile
Paul Sack
NPI 1598707606
$8,049.45
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $5,117 · 2021: $275 · 2022: $197 · 2023: $394 · 2024: $1,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,575 · Food and Beverage: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,575.00 |
| Food and Beverage | $439.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,047.89 | 2019-2022 | |
| Novo Nordisk INC | $1,747.10 | 2019-2024 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $131.61 | 2019-2023 | |
| Beta Bionics, INC. | $125.34 | 2023 | Ilet Bionic Pancreas |
| Dexcom, INC. | $118.35 | 2021-2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $102.74 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.47 | 2019-2023 | Jardiance |
| Xeris Pharmaceuticals, INC. | $64.96 | 2021-2023 | Recorlev |
| Recordati_rare_diseases_inc. | $59.67 | 2021-2023 | Signifor Lar, Isturisa |
| Valeritas, INC. | $54.26 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.64 | 2021-2022 | |
| Abbvie INC. | $36.94 | 2021 | |
| Insulet Corporation | $36.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.29 | 2023 | |
| Lifescan, INC. | $31.15 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $29.49 | 2022 | |
| Amgen INC. | $27.38 | 2019 | |
| Corcept Therapeutics | $26.58 | 2024 | Korlym |
| Acerus Pharmaceuticals Corporation | $25.52 | 2021 | |
| Kyowa Kirin, INC. | $23.12 | 2023 | Crysvita |
| Amarin Pharma, INC. | $21.57 | 2020 | |
| Esperion Therapeutics, INC. | $21.20 | 2022 | |
| Cequr Corporation | $20.00 | 2023 | Cequr Simplicity |
| Ipsen Biopharmaceuticals, INC | $19.12 | 2019 | |
| Shire North American Group INC | $19.07 | 2019 | |
| Gilead Sciences, INC. | $18.06 | 2019 | |
| Horizon Therapeutics Plc | $17.94 | 2021 | |
| Zealand Pharma US, INC. | $17.49 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.76 | 2019 | |
| Medtronic Minimed, INC. | $15.52 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.70 | 2021 | |
| Companion Medical, INC. | $12.60 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Sack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.